Sapap3 deletion causes dynamic synaptic density abnormalities: a longitudinal [

Autoradiography Grooming Obsessive–compulsive disorder (OCD) Positron emission tomography (PET) SAP90/PSD-95-associated protein 3 (Sapap3) Synaptic vesicle protein 2A (SV2A) [11C]UCB-J [3H]UCB-J

Journal

EJNMMI research
ISSN: 2191-219X
Titre abrégé: EJNMMI Res
Pays: Germany
ID NLM: 101560946

Informations de publication

Date de publication:
13 Nov 2020
Historique:
received: 24 07 2020
accepted: 20 10 2020
entrez: 13 11 2020
pubmed: 14 11 2020
medline: 14 11 2020
Statut: epublish

Résumé

Currently, the evidence on synaptic abnormalities in neuropsychiatric disorders-including obsessive-compulsive disorder (OCD)-is emerging. The newly established positron emission tomography (PET) ligand ((R)-1-((3-((11)C-methyl-(11)C)pyridin-4-yl)methyl)-4-(3,4,5-trifluorophenyl)pyrrolidin-2-one) ([ Longitudinal [ At the age of 3 months, Sapap3 ko mice are already characterized by a significantly lower SV2A availability compared to wt littermates (i.a. cortex - 12.69%, p < 0.01; striatum - 14.12%, p < 0.001, thalamus - 13.11%, p < 0.001, and hippocampus - 12.99%, p < 0.001). Healthy ageing in control mice was associated with a diffuse and significant (p < 0.001) decline throughout the brain, whereas in Sapap3 ko mice this decline was more confined to the corticostriatal level. A strong linear relationship (p < 0.0001) was established between the outcome parameters of [ [

Sections du résumé

BACKGROUND BACKGROUND
Currently, the evidence on synaptic abnormalities in neuropsychiatric disorders-including obsessive-compulsive disorder (OCD)-is emerging. The newly established positron emission tomography (PET) ligand ((R)-1-((3-((11)C-methyl-(11)C)pyridin-4-yl)methyl)-4-(3,4,5-trifluorophenyl)pyrrolidin-2-one) ([
METHODS METHODS
Longitudinal [
RESULTS RESULTS
At the age of 3 months, Sapap3 ko mice are already characterized by a significantly lower SV2A availability compared to wt littermates (i.a. cortex - 12.69%, p < 0.01; striatum - 14.12%, p < 0.001, thalamus - 13.11%, p < 0.001, and hippocampus - 12.99%, p < 0.001). Healthy ageing in control mice was associated with a diffuse and significant (p < 0.001) decline throughout the brain, whereas in Sapap3 ko mice this decline was more confined to the corticostriatal level. A strong linear relationship (p < 0.0001) was established between the outcome parameters of [
CONCLUSIONS CONCLUSIONS
[

Identifiants

pubmed: 33185747
doi: 10.1186/s13550-020-00721-2
pii: 10.1186/s13550-020-00721-2
pmc: PMC7666267
doi:

Types de publication

Journal Article

Langues

eng

Pagination

140

Subventions

Organisme : Universiteit Antwerpen
ID : 41/FA020000/FFB140317
Organisme : Fonds Wetenschappelijk Onderzoek
ID : 42/FA020000/685

Références

Nat Med. 2010 May;16(5):598-602, 1p following 602
pubmed: 20418887
J Nucl Med. 2020 Jan;61(1):96-103
pubmed: 31324712
J Neurosci. 2019 Apr 10;39(15):2965-2975
pubmed: 30737313
Nature. 2011 Apr 28;472(7344):437-42
pubmed: 21423165
J Immunol Res. 2016;2016:8606057
pubmed: 28053994
Biol Psychiatry. 2016 Oct 1;80(7):522-33
pubmed: 27436084
Proc Natl Acad Sci U S A. 1999 Dec 21;96(26):15268-73
pubmed: 10611374
Nature. 2016 Feb 11;530(7589):177-83
pubmed: 26814963
Cell Rep. 2017 Dec 26;21(13):3781-3793
pubmed: 29281827
Biol Psychiatry. 1998 May 1;43(9):623-40
pubmed: 9582996
Cell. 2016 May 5;165(4):921-35
pubmed: 27114033
Nature. 2007 Aug 23;448(7156):894-900
pubmed: 17713528
Lancet. 2009 Aug 8;374(9688):491-9
pubmed: 19665647
Front Neurol. 2018 Jun 29;9:516
pubmed: 30013509
Mol Imaging Biol. 2020 Oct;22(5):1290-1300
pubmed: 32514885
Neuropharmacology. 2020 Oct 15;177:108160
pubmed: 32454126
Lab Anim. 2013 Jan;47(1):12-8
pubmed: 23349451
J Child Neurol. 2015 Jun;30(7):942-4
pubmed: 25008911
Neuron. 2000 Nov;28(2):343-7
pubmed: 11144344
Am J Med Genet B Neuropsychiatr Genet. 2009 Jul 5;150B(5):710-20
pubmed: 19051237
BMC Neurosci. 2013 Aug 09;14:87
pubmed: 23937191
J Neurosci. 2011 Nov 16;31(46):16685-91
pubmed: 22090495
Curr Opin Neurobiol. 2011 Dec;21(6):842-8
pubmed: 21605970
Nat Rev Neurosci. 2004 Oct;5(10):771-81
pubmed: 15378037
Am J Psychiatry. 2010 Dec;167(12):1508-17
pubmed: 20952458
J Nucl Med. 2016 May;57(5):777-84
pubmed: 26848175
J Cereb Blood Flow Metab. 2020 Jun;40(6):1351-1362
pubmed: 31307287
Eur J Nucl Med. 1998 Feb;25(2):173-6
pubmed: 9473266
Neuron. 2013 Apr 10;78(1):8-27
pubmed: 23583105
Brain Res. 2019 Jul 15;1715:73-83
pubmed: 30905653
Trends Cogn Sci. 2012 Jan;16(1):43-51
pubmed: 22138231
Nat Rev Neurosci. 2016 Apr;17(4):209-23
pubmed: 26988743
Neuroscience. 2016 May 3;321:121-137
pubmed: 26562431
Arch Gen Psychiatry. 2010 Oct;67(10):1061-8
pubmed: 20921122
Nat Commun. 2019 Apr 4;10(1):1529
pubmed: 30948709
Mol Psychiatry. 2013 Jul;18(7):788-98
pubmed: 22889921
Mol Psychiatry. 2015 Mar;20(3):337-44
pubmed: 24821223
Biol Psychiatry. 2014 Apr 15;75(8):623-30
pubmed: 23414593
Mol Psychiatry. 2018 Feb;23(2):444-458
pubmed: 28070119
Nat Genet. 2010 Jun;42(6):478-9
pubmed: 20502490
Curr Psychiatry Rep. 2016 Oct;18(10):90
pubmed: 27549605
Mol Psychiatry. 2009 Jan;14(1):6-9
pubmed: 19096451
J Cereb Blood Flow Metab. 1990 Sep;10(5):740-7
pubmed: 2384545
Prog Neuropsychopharmacol Biol Psychiatry. 2018 Mar 2;82:187-194
pubmed: 29169997
Sci Transl Med. 2016 Jul 20;8(348):348ra96
pubmed: 27440727
Proc Natl Acad Sci U S A. 2004 Jun 29;101(26):9861-6
pubmed: 15210974
Nat Med. 2012 Sep;18(9):1413-7
pubmed: 22885997
Mol Psychiatry. 2018 Sep;23(9):1868-1877
pubmed: 28948967
Mol Cell Neurosci. 2019 Jun;97:34-42
pubmed: 30796959
Nat Rev Neurosci. 2015 Sep;16(9):551-63
pubmed: 26289574
Proc Natl Acad Sci U S A. 2017 Jun 20;114(25):6599-6604
pubmed: 28584117
Nat Rev Neurosci. 2014 Jun;15(6):410-24
pubmed: 24840803
Neuroimage. 2010 Nov 1;53(2):365-72
pubmed: 20600960
J Neurosci. 2011 Jun 29;31(26):9563-73
pubmed: 21715621
J Cereb Blood Flow Metab. 2020 Jun 14;:271678X20931140
pubmed: 32538280
Neuron. 2001 Jul 19;31(1):115-30
pubmed: 11498055
Sci Rep. 2019 Jun 19;9(1):8741
pubmed: 31217515
J Clin Invest. 2016 Jan;126(1):303-17
pubmed: 26657857
Science. 2013 Jun 7;340(6137):1243-6
pubmed: 23744950
Am J Psychiatry. 2005 Feb;162(2):228-38
pubmed: 15677583
Nat Neurosci. 2003 Jul;6(7):708-16
pubmed: 12796785
Curr Opin Neurobiol. 2012 Jun;22(3):522-9
pubmed: 22409856
Annu Rev Neurosci. 2012;35:49-71
pubmed: 22540979
J Neurosci. 2010 Feb 10;30(6):2115-29
pubmed: 20147539
Mol Psychiatry. 2010 Jan;15(1):53-63
pubmed: 18725912
ILAR J. 2007;48(4):356-73
pubmed: 17712222
Front Hum Neurosci. 2016 Nov 08;10:566
pubmed: 27877121
Epilepsy Behav Case Rep. 2014 Jan 08;2:15-6
pubmed: 25667858
Semin Cell Dev Biol. 2019 Nov;95:130-141
pubmed: 30826548
Neurosci Biobehav Rev. 2009 Jun;33(6):818-30
pubmed: 19428494

Auteurs

Dorien Glorie (D)

Molecular Imaging Center Antwerp (MICA), University of Antwerp, Universiteitsplein 1, Wilrijk, Belgium.

Jeroen Verhaeghe (J)

Molecular Imaging Center Antwerp (MICA), University of Antwerp, Universiteitsplein 1, Wilrijk, Belgium.

Alan Miranda (A)

Molecular Imaging Center Antwerp (MICA), University of Antwerp, Universiteitsplein 1, Wilrijk, Belgium.

Stef De Lombaerde (S)

Molecular Imaging Center Antwerp (MICA), University of Antwerp, Universiteitsplein 1, Wilrijk, Belgium.
Department of Nuclear Medicine, Antwerp University Hospital, Edegem, Belgium.

Sigrid Stroobants (S)

Molecular Imaging Center Antwerp (MICA), University of Antwerp, Universiteitsplein 1, Wilrijk, Belgium.
Department of Nuclear Medicine, Antwerp University Hospital, Edegem, Belgium.

Steven Staelens (S)

Molecular Imaging Center Antwerp (MICA), University of Antwerp, Universiteitsplein 1, Wilrijk, Belgium. steven.staelens@uantwerpen.be.

Classifications MeSH